-
1Academic Journal
Συγγραφείς: A. S. Potapov, A. E. Pushkareva, A. V. Vinokurova, M. O. Prokhorenkova, A. E. Krasnovidova, А. С. Потапов, А. Е. Пушкарева, А. В. Винокурова, М. О. Прохоренкова, А. Е. Красновидова
Πηγή: Meditsinskiy sovet = Medical Council; № 13 (2024); 124-129 ; Медицинский Совет; № 13 (2024); 124-129 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: упадацитиниб, Janus kinase inhibitor, targeted immunosuppressants, selective immunosuppressants, small molecules, biological therapy, upadacitinib, ингибитор янус-киназ, таргетные иммуносупрессоры, селективные иммунодепрессанты, малые молекулы, биологическая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8506/7477; Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(7):769-784. https://doi.org/10.1093/ecco-jcc/jjx009.; Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. https://doi.org/10.1136/bmj.j2505.; Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(8):989-997. https://doi.org/10.1093/ecco-jcc/jjw053.; Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7(1):e135. https://doi.org/10.1038/ctg.2015.63.; Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019;35(4):302-310. https://doi.org/10.1097/MOG.0000000000000536.; Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015;35(4):412-423. https://doi.org/10.1002/phar.1561.; Hajjat TM, Mosha M, Whaley KG, Rosen MJ, Suppa C, Markowitz J et al. Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study. Crohns Colitis 360. 2021;3(3):otab039. https://doi.org/10.1093/crocol/otab039.; Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719-729. https://doi.org/10.1038/nm.3895.; Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci. 2021;22(21):11322. https://doi.org/10.3390/ijms222111322.; De Vries LCS, Wildenberg ME, De Jonge WJ, D'Haens GR. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017;11(7):885-893. https://doi.org/10.1093/ecco-jcc/jjx003.; Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13(7):693-703. https://doi.org/10.1080/1744666X.2017.1291342.; Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1-8. https://doi.org/10.1016/j.phrs.2013.06.007.; Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023;83(4):299-314. https://doi.org/10.1007/s40265-023-01840-5.; Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(12):2010-2022. https://doi.org/10.1093/ibd/izab037.; Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020;158(8):2123-2138.e8. https://doi.org/10.1053/j.gastro.2020.01.047.; Irani M, Fan C, Glassner K, Abraham BP. Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes. Clin Exp Gastroenterol. 2023;16:21-28. https://doi.org/10.2147/CEG.S367086.; Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. https://doi.org/10.1016/S0140-6736(22)00581-5.; D'Haens G, Panes J, Louis E, Lacerda A, Zhou Q, Liu J, Loftus EV Jr. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. Clin Gastroenterol Hepatol. 2022;20(10):2337-2346.e3. https://doi.org/10.1016/j.cgh.2021.12.030.; Chugh R, Braga-Neto MB, Fredrick TW, Ramos GP, Terdiman J, El-Nachef N et al. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease. J Crohns Colitis. 2023;17(4):504-512. https://doi.org/10.1093/ecco-jcc/jjac157.; Miller M, Patel AS, Pasternak B. Rescue therapy with upadacitinib in medically refractory pediatric ulcerative colitis. JPGN Rep. 2024;5(2):197-199. https://doi.org/10.1002/jpr3.12067.; Kontaki E, Merchant A, Gaynor E, Kiparissi F. P494 Efficacy and safety of Upadacitinib in moderate to severe paediatric Crohn's disease and ulcerative colitis in a tertiary Paediatric IBD (PIBD) centre - A case series. J Crohns Colitis. 2024;18(1 Suppl.):i986. https://doi.org/10.1093/ecco-jcc/jjad212.0624.; Spencer EA, Bergstein S, Dolinger M, Pittman N, Kellar A, Dunkin D, Dubinsky MC. Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023:izad300. https://doi.org/10.1093/ibd/izad300.; Collen LV. Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease. Inflamm Bowel Dis. 2023;29(7):1175-1176. https://doi.org/10.1093/ibd/izad048.; Martinez-Vinson C, Lengliné H, Viala J. G-PP225 Upadacitinib: The Robert Debre Experience. JPGN Rep. 2024;5(1 Suppl.):S767. https://doi.org/10.1002/jpr3.12073.; Nedelkopoulou N, Sharma S. G-EPV158 Upadacitinib For Difficult-To-Treat Paediatric Ibd; A Single Centre Experience. JPGN Rep. 2024;5(1 Suppl.):S519. https://doi.org/10.1002/jpr3.12073.
-
2Academic Journal
Συγγραφείς: E. N. Koltsova, G. V. Lukina, E. I. Schmidt, K. A. Lytkina, E. V. Zhilyaev, Е. Н. Кольцова, Г. В. Лукина, Е. И. Шмидт, К. A. Лыткина, Е. В. Жиляев
Πηγή: Modern Rheumatology Journal; Том 16, № 6 (2022); 26-31 ; Современная ревматология; Том 16, № 6 (2022); 26-31 ; 2310-158X ; 1996-7012
Θεματικοί όροι: инфекционные осложнения, biologic disease modifying antirheumatic drugs, targeted immunosuppressive agents, adverse events, infectious complications, генно-инженерные биологические препараты, таргетные иммуносупрессоры, нежелательные явления
Περιγραφή αρχείου: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1368/1308; Муравьев ЮВ, Гриднева ГИ, Муравьева ЛА и др. Основания для отмены базисных противовоспалительных препаратов, генно-инженерных биологических препаратов и тофацитиниба при ревматоидном артрите. Современная ревматология. 2018; 11(4):101-5. doi:10.14412/1996-7012-2018-4-101-105; Муравьев ЮВ. Какие неблагоприятные реакции на генно-инженерные биологические препараты относят к парадоксальным? Научно-практическая ревматология. 2018;56(4):531-4.; Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008 Mar;35(3):387-93. Epub 2008 Feb 1.; Van Vollenhoven RF, Emery P, Bingham CO3rd. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial program with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013 Sep 1;72(9):1496-502. doi:10.1136/annrheumdis-2012-201956. Epub 2012 Nov 7.; Quartuccio L. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. Journal of Advanced Research. 2019;15:87-93.; Simon TA, Askling J, Lacaille D. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther. 2010;12(2): R67. doi:10.1186/ar2984. Epub 2010 Apr 14.; Souto A, Maneiro JR, Gуmez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016 Mar;55(3):523-34. doi:10.1093/rheumatology/kev374. Epub 2015 Oct 21.; Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a metaanalysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208-32. doi:10.1016/j.amjmed.2014.06.012. Epub 2014 Jun 17.; Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun; 76(6):1101-36. doi:10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15.; Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010 Sep;62(9): 2625-32. doi:10.1002/art.27555.; Askling J, CM Fored, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007 Oct;66(10):1339-44. doi:10.1136/ard.2006.062760. Epub 2007 Jan 29.; Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011 Apr;70(4):616-23. doi:10.1136/ard.2010.137422. Epub 2010 Dec 21.; Singh JA, Wells GA, Christensen R. Adverse effects of biologics: a network metaanalysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;2011(2): CD008794. doi:10.1002/14651858.CD008794.pub2.; Carrara G, Bortoluzzi A, Sakellariou G, et al. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clin Exp Rheumatol. 2019 Jan-Feb;37(1):60-6. Epub 2018 Jul 18.; Iwanaga N, Arima K, Terada K, et al. Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study. Int J Rheum Dis. 2017 Mar;20(3):346-52. doi:10.1111/1756-185X.12348. Epub 2014 Apr 10.; Machado MAA, de Moura CS, Guerra SF, et al. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther. 2018 Mar 23;20(1):60. doi:10.1186/s13075-018-1539-6.; Cecconi M, Ranza R, Titton DC, et al. Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondy-loarthritis on Biologic Drugs-Data From the Brazilian Registry for Biologics Monitoring. J Clin Rheumatol. 2020 Mar;26(2):73-8. doi:10.1097/RHU.0000000000000935.; Lampropoulos CE, Orfanos P, Bournia VK. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):216-24. Epub 2015 Feb 9.; Sakai R, Cho SK, Nanki T, et al. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther. 2015 Mar 23;17(1):74. doi:10.1186/s13075-015-0583-8.; Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015 Jul 18;386(9990):258-65. doi:10.1016/S0140-6736(14)61704-9. Epub 2015 May 11.; Canete JD, Hernandez MV, Sanmarti R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin Biol Ther. 2017 Sep;17(9):1089-103. doi:10.1080/14712598.2017.1346078. Epub 2017 Jul 17.; Leon L, Gomez A, Vadillo C. Severe adverse drug reactions to biological diseasemodifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol. 2018 Jan-Feb; 36(1):29-35. Epub 2017 Jun 6.; Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adali-mumab, etanercept and infliximab. Ann Rheum Dis. 2015 Feb;74(2):354-60. doi:10.1136/annrheumdis-2013-204128. Epub 2013 Nov 27.